Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

NF-κB dysregulation in SMZL represents a new biological basis for novel therapeutic strategies for SMZL patients. Proteasome inhibitors, that are already approved for other malignancies, or more specific anti-NF-κB compounds under development should be tested for their efficacy in clinical trials specifically dedicated to SMZL.